

## Anti-CD20/CD3 Antibody (Mosunetuzumab)

### Introduction

Mosunetuzumab is a bispecific antibody derived from genetic engineering technology. It is mainly composed of two different monoclonal antibody fragments and can bind to CD20 and CD3 molecules at the same time. Its mechanism is to activate the killing effect of T cells on B cells by connecting T cells (through CD3) and B cells (through CD20). Mosunetuzumab is mainly used to treat relapsed or refractory B-cell non-Hodgkin's lymphoma.

### Product parameters

Alternative Names	BTCT4465A
Target Accession	-
Target	CD20/CD3
CAS number	1905409-39-3
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

